EUVIMEDEUVIMED entdecken
Crossref

Risk Factors for Lenvatinib-Induced High-Grade Hypothyroidism in Patients with Hepatocellular Carcinoma: A Retrospective Study

Shusuke Uekusa, Maho Nemoto, Yuki Hanai, Misaki Nakashin, Arisu Miyagawa, Sachiko Yanagino, Yoshiki Arita, Takahiro Matsumoto, Kenji Nishizawa, Hidenari Nagai, Koji Higai, Kazuhiro Matsuo

Pharmacology · 2023

DOI: 10.1159/000531881 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacology, 2023. Verfasst von Shusuke Uekusa und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University, Chiba, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Hypothyroidism. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Lenvatinib mesylate (LEN) is an orally administered tyrosine kinase inhibitor used for the treatment of various cancers, including hepatocellular carcinoma (HCC). HCC treatment with LEN is associated with a very high incidence of adverse events, especially hypothyroidism. This study investigated the incidence of hypothyroidism due to LEN and the relationships between hypothyroidism incidence and patient demographics by analyzing clinical laboratory data from HCC patients treated with LEN.

Methods

This was a single-center, retrospective study of HCC patients who received LEN between April 19, 2018, and September 30, 2020. The observation period was from 1 week before the start of LEN administration to 1 month after the end of administration.

Results

In total, 61 patients with HCC were enrolled. High-grade hypothyroidism (CTCAE Grade 2–3) was found in 36.1% (22/61 patients). In high-grade hypothyroidism, eosinophil (EOSINO) count was significantly low (p = 0.029). The cutoff value of EOSINO count was estimated to be approximately 150/µL. The adjusted odds ratios of high-grade hypothyroidism for current smoking and EOSINO count <150/µL were 0.237 (95% confidence interval: 0.063–0.893) and 4.219 (95% confidence interval: 1.119–15.92), respectively.

Conclusion

The results showed that noncurrent smoking and EOSINO count <150/µL are risk factors for LEN-induced high-grade hypothyroidism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHypothyroidismHumansRetrospective StudiesRisk FactorsPhenylurea CompoundsQuinolines

Stichwörter der Autor:innen

EosinophilsHepatocellular carcinomaHypothyroidismLenvatinibSmoking

Substanzen

lenvatinibPhenylurea CompoundsQuinolines

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University, Chiba, Japan.
  • Toho University Omori Medical Center, Tokyo, Japan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan.
  • Laboratory of Medical Biochemistry, Faculty of Pharmaceutical Sciences, Toho University, Chiba, Japan.

Zitieren

APA

Uekusa, S., Nemoto, M., Hanai, Y., Nakashin, M., Miyagawa, A., Yanagino, S., Arita, Y., Matsumoto, T., Nishizawa, K., Nagai, H., Higai, K., & Matsuo, K. (2023). Risk Factors for Lenvatinib-Induced High-Grade Hypothyroidism in Patients with Hepatocellular Carcinoma: A Retrospective Study. Pharmacology. https://doi.org/10.1159/000531881

Vancouver

Uekusa S, Nemoto M, Hanai Y, Nakashin M, Miyagawa A, Yanagino S, et al. Risk Factors for Lenvatinib-Induced High-Grade Hypothyroidism in Patients with Hepatocellular Carcinoma: A Retrospective Study. Pharmacology. 2023. doi:10.1159/000531881

BibTeX
@article{Uekusa2023,
  author = {Uekusa, Shusuke and Nemoto, Maho and Hanai, Yuki and Nakashin, Misaki and Miyagawa, Arisu and Yanagino, Sachiko and Arita, Yoshiki and Matsumoto, Takahiro and Nishizawa, Kenji and Nagai, Hidenari and Higai, Koji and Matsuo, Kazuhiro},
  title = {Risk Factors for Lenvatinib-Induced High-Grade Hypothyroidism in Patients with Hepatocellular Carcinoma: A Retrospective Study},
  journal = {Pharmacology},
  year = {2023},
  doi = {10.1159/000531881}
}
Kostenlos starten →